BR112014018843A2 - animal não humano, célula, hibridoma, método para produzir uma proteína e para modificar um locus de cadeia pesada de imunoglibulina de um roedor, e, roedor - Google Patents

animal não humano, célula, hibridoma, método para produzir uma proteína e para modificar um locus de cadeia pesada de imunoglibulina de um roedor, e, roedor

Info

Publication number
BR112014018843A2
BR112014018843A2 BR112014018843A BR112014018843A BR112014018843A2 BR 112014018843 A2 BR112014018843 A2 BR 112014018843A2 BR 112014018843 A BR112014018843 A BR 112014018843A BR 112014018843 A BR112014018843 A BR 112014018843A BR 112014018843 A2 BR112014018843 A2 BR 112014018843A2
Authority
BR
Brazil
Prior art keywords
rodent
hybridoma
modifying
protein
cell
Prior art date
Application number
BR112014018843A
Other languages
English (en)
Other versions
BR112014018843B1 (pt
BR112014018843A8 (pt
Inventor
J Murphy Andrew
Gurer Cagan
A Meagher Karolina
Macdonald Lynn
Stevens Sean
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014018843A2 publication Critical patent/BR112014018843A2/pt
Publication of BR112014018843A8 publication Critical patent/BR112014018843A8/pt
Publication of BR112014018843B1 publication Critical patent/BR112014018843B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
BR112014018843-2A 2012-02-01 2013-02-01 Métodos para obter um camundongo, para obter um camundongo geneticamente modificado, para produzir uma proteína e para modificar um locus de cadeia pesada de imunoglobulina de um camundongo BR112014018843B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US61/593,463 2012-02-01
US201261677538P 2012-07-31 2012-07-31
US61/677,538 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (3)

Publication Number Publication Date
BR112014018843A2 true BR112014018843A2 (pt) 2017-07-04
BR112014018843A8 BR112014018843A8 (pt) 2019-01-29
BR112014018843B1 BR112014018843B1 (pt) 2024-02-20

Family

ID=47714588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018843-2A BR112014018843B1 (pt) 2012-02-01 2013-02-01 Métodos para obter um camundongo, para obter um camundongo geneticamente modificado, para produzir uma proteína e para modificar um locus de cadeia pesada de imunoglobulina de um camundongo

Country Status (26)

Country Link
US (3) US20130212719A1 (pt)
EP (3) EP3597038B1 (pt)
JP (6) JP2015505477A (pt)
KR (2) KR20190006029A (pt)
CN (2) CN104202971B (pt)
AU (3) AU2013204758B2 (pt)
BR (1) BR112014018843B1 (pt)
CA (1) CA2863175A1 (pt)
CY (2) CY1122419T1 (pt)
DK (2) DK2809150T3 (pt)
ES (2) ES2870703T3 (pt)
HK (1) HK1202771A1 (pt)
HR (2) HRP20192218T1 (pt)
HU (2) HUE055610T2 (pt)
IL (3) IL233827A0 (pt)
LT (2) LT2809150T (pt)
ME (1) ME03611B (pt)
MX (2) MX2020003491A (pt)
NZ (3) NZ719228A (pt)
PL (2) PL2809150T3 (pt)
PT (2) PT2809150T (pt)
RS (2) RS59699B1 (pt)
RU (2) RU2664185C2 (pt)
SG (3) SG10201606256TA (pt)
SI (2) SI2809150T1 (pt)
WO (1) WO2013116609A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9516868B2 (en) 2010-08-02 2016-12-13 Regeneron Pharmaceuticals, Inc. Mice that make VL binding proteins
PL3572517T3 (pl) 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
JP5813880B2 (ja) 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
NZ717848A (en) 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
PT2840892T (pt) 2013-02-20 2018-07-20 Regeneron Pharma Animais não humanos com sequências da cadeia pesada da imunoglobulina modificada
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2018183946A1 (en) * 2017-03-30 2018-10-04 Utah State University Transgenic silkworms expressing spider silk
CA3084049A1 (en) * 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
WO2019190922A1 (en) * 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR102617284B1 (ko) * 2018-06-14 2023-12-27 리제너론 파마슈티칼스 인코포레이티드 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
AU8470301A (en) * 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
CN1852925A (zh) * 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
US20060117398A1 (en) * 2004-10-22 2006-06-01 Roland Buelow Suppression of endogenous immunoglobulin expression
US7910798B2 (en) * 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ATE536374T1 (de) * 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
EP2195346B1 (en) * 2007-08-30 2018-01-03 The Walter and Eliza Hall Institute of Medical Research Dendritic cell marker and uses thereof
KR102225009B1 (ko) * 2007-09-26 2021-03-08 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
EP3456190B1 (en) * 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
BRPI0917352A2 (pt) * 2008-08-29 2017-08-22 Symphogen As Métodos para produção de uma biblioteca de pares cognatos que compreende sequências ligadas que codificam regiões variáveis e para gerar um vetor que codifica um anticorpo quimérico com regiões de seres humanos constantes e regiões variáveis não humanas, biblioteca de vetores, e método para produção de uma biblioteca de sequências de imunoglobulina derivadas de aves
WO2010091182A2 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US9516868B2 (en) * 2010-08-02 2016-12-13 Regeneron Pharmaceuticals, Inc. Mice that make VL binding proteins
KR101387377B1 (ko) * 2011-02-25 2014-04-21 리제너론 파아마슈티컬스, 인크. Ａｄａｍ６ 마우스
PL3572517T3 (pl) * 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
RU2664181C2 (ru) * 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
NZ717848A (en) * 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
LT3407709T (lt) * 2016-11-04 2020-10-12 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą

Also Published As

Publication number Publication date
JP2015505477A (ja) 2015-02-23
MX2020003491A (es) 2022-10-25
AU2015246154B2 (en) 2017-11-23
ME03611B (me) 2020-07-20
EP3912465A1 (en) 2021-11-24
JP7187615B2 (ja) 2022-12-12
IL233827A0 (en) 2014-09-30
RU2770016C2 (ru) 2022-04-14
DK3597038T3 (da) 2021-06-28
SG11201404477YA (en) 2014-08-28
KR20190006029A (ko) 2019-01-16
CN106117364B (zh) 2021-08-31
CN104202971B (zh) 2016-07-06
CA2863175A1 (en) 2013-08-08
CY1124361T1 (el) 2022-07-22
AU2017251848A1 (en) 2017-11-16
CN106117364A (zh) 2016-11-16
LT2809150T (lt) 2019-10-25
EP2809150A1 (en) 2014-12-10
EP2809150B1 (en) 2019-09-18
AU2015246154A1 (en) 2015-11-12
BR112014018843B1 (pt) 2024-02-20
EP3597038A1 (en) 2020-01-22
AU2017251848B2 (en) 2020-02-20
HRP20192218T1 (hr) 2020-03-06
US20210368751A1 (en) 2021-12-02
LT3597038T (lt) 2021-05-25
SG10201606256TA (en) 2016-09-29
CY1122419T1 (el) 2021-01-27
AU2013204758A1 (en) 2013-08-15
HRP20210987T1 (hr) 2021-09-17
EP3597038B1 (en) 2021-04-21
IL268675A (en) 2019-10-31
JP2023014242A (ja) 2023-01-26
AU2013204758B2 (en) 2015-07-23
JP6942757B2 (ja) 2021-09-29
IL268675B (en) 2020-11-30
NZ627977A (en) 2016-06-24
US20170094955A1 (en) 2017-04-06
PL3597038T3 (pl) 2021-11-08
HUE046744T2 (hu) 2020-03-30
SI3597038T1 (sl) 2021-07-30
MX2019002517A (es) 2019-06-17
KR20140123983A (ko) 2014-10-23
RU2664185C2 (ru) 2018-08-15
RS62023B1 (sr) 2021-07-30
SI2809150T1 (sl) 2019-11-29
RU2018122695A (ru) 2019-03-06
HUE055610T2 (hu) 2021-12-28
PT2809150T (pt) 2019-12-09
ES2753774T3 (es) 2020-04-14
NZ719228A (en) 2022-08-26
WO2013116609A1 (en) 2013-08-08
NZ734504A (en) 2022-10-28
JP2023168590A (ja) 2023-11-24
DK2809150T3 (da) 2019-12-09
PT3597038T (pt) 2021-05-10
RS59699B1 (sr) 2020-01-31
IL261280B (en) 2019-08-29
IL261280A (en) 2018-10-31
JP2021137030A (ja) 2021-09-16
PL2809150T3 (pl) 2020-04-30
RU2018122695A3 (pt) 2021-10-06
JP2018075041A (ja) 2018-05-17
JP6698718B2 (ja) 2020-05-27
US20130212719A1 (en) 2013-08-15
HK1202771A1 (en) 2015-10-09
RU2014133653A (ru) 2016-03-20
JP2019170395A (ja) 2019-10-10
CN104202971A (zh) 2014-12-10
SG10201913428QA (en) 2020-03-30
ES2870703T3 (es) 2021-10-27
BR112014018843A8 (pt) 2019-01-29

Similar Documents

Publication Publication Date Title
BR112014018843A2 (pt) animal não humano, célula, hibridoma, método para produzir uma proteína e para modificar um locus de cadeia pesada de imunoglibulina de um roedor, e, roedor
DK3597037T3 (da) Humaniserede, ikke-humane dyr med afgrænsede immunoglobulin-tungkædeloci
HRP20160484T1 (hr) Životinje koje izražavaju antitijela sa zajedničkim lakim lancem
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
BR112014014583A2 (pt) método para produção de uma ração animal, e, ração animal
DK2817333T3 (da) Bispecifikke, asymmetriske igg4-antistoffer
IL266282A (en) Non-human animals with a transgenic immunoglobulin light chain locus
BR112013002290A2 (pt) método para controlar estrutura de cadeia de copolímeros
FI20100384A (fi) Menetelmä soluissa tapahtuvan proteiinien diffuusion mallintamiseksi

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011479-5 PROTOCOLO 870230049854 EM 12/06/2023 12:23.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.